AKT1 and cancer: Considering that some studies showed AKT activation to play a role in PARPi resistance in cancer (25), that DNAPK can mediate AKT activation and apoptosis inhibition in platinum resistance (26) and that AKT2 was identified only in the UWB+B cells to be ADP-ribosylated, we next evaluated AKT PARylation upon rucaparib treatment.